Procore signs multi-year strategic collaboration agreement with AWS
Investing.com - Larimar Therapeutics Inc reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Larimar Therapeutics Inc announced earnings per share of $-0.370 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.587 on revenue of $0.00.
Larimar Therapeutics Inc 's are down 4.96% and is trading at $3.050 , still down 77.52% from its 52 week high of $13.57 set on Wednesday, November 10, 2021.
Larimar Therapeutics Inc shares gained 3.04% to trade at $3.050 in intra-day trade the report.
Larimar Therapeutics Inc follows other major Healthcare sector earnings this month
Larimar Therapeutics Inc's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar